PLIANT THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
PLIANT THERAPEUTICS, INC. (PLRX) reported Share-based Payment Arrangement, Expense of $4.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $4.19M, a 34.41% decline year-over-year.
- PLIANT THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $4.25M, a 52.27% decline year-over-year.
- PLIANT THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $4.53M, a 46.22% decline year-over-year.
- PLIANT THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $6.42M, a 27.88% decline year-over-year.
- PLIANT THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $26.24M, a 30.27% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $37.63M, a 15.41% decline from fiscal 2023.
- PLIANT THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $44.48M, a 96.84% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $22.60M, a 116.52% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.19M 10-Q · filed 2026-08-11 | $8.44M 10-Q · filed 2026-08-11 | $12.97M derived: sum of 3 quarters · filed 2026-08-11 | $19.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.25M 10-Q · filed 2026-05-11 | $8.78M derived: sum of 2 quarters · filed 2026-05-11 | $15.20M derived: sum of 3 quarters · filed 2026-05-11 | $21.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $10.95M derived: sum of 2 quarters · filed 2026-03-11 | $17.33M derived: sum of 3 quarters · filed 2026-08-11 | $26.24M 10-K · filed 2026-03-11 |
| 2025-09-30 | $6.42M 10-Q · filed 2025-11-06 | $12.80M derived: sum of 2 quarters · filed 2026-08-11 | $21.71M 10-Q · filed 2025-11-06 | $30.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $6.38M 10-Q · filed 2026-08-11 | $15.29M 10-Q · filed 2026-08-11 | $23.71M derived: sum of 3 quarters · filed 2026-08-11 | $32.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $8.91M 10-Q · filed 2026-05-11 | $17.33M derived: sum of 2 quarters · filed 2026-05-11 | $26.23M derived: sum of 3 quarters · filed 2026-05-11 | $36.87M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $8.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $17.32M derived: sum of 2 quarters · filed 2026-03-11 | $27.96M derived: sum of 3 quarters · filed 2026-03-11 | $37.63M 10-K · filed 2026-03-11 |
| 2024-09-30 | $8.90M 10-Q · filed 2025-11-06 | $19.54M derived: sum of 2 quarters · filed 2025-11-06 | $29.21M 10-Q · filed 2025-11-06 | $38.36M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $10.64M 10-Q · filed 2025-08-07 | $20.31M 10-Q · filed 2025-08-07 | $29.46M derived: sum of 3 quarters · filed 2025-08-07 | $39.83M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $9.67M 10-Q · filed 2025-05-08 | $18.82M derived: sum of 2 quarters · filed 2025-05-08 | $29.18M derived: sum of 3 quarters · filed 2025-05-08 | $42.23M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $9.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $19.52M derived: sum of 2 quarters · filed 2025-03-03 | $32.56M derived: sum of 3 quarters · filed 2025-03-03 | $44.48M 10-K · filed 2025-03-03 |
| 2023-09-30 | $10.36M 10-Q · filed 2024-11-07 | $23.41M derived: sum of 2 quarters · filed 2024-11-07 | $35.33M 10-Q · filed 2024-11-07 | $46.19M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $13.05M 10-Q · filed 2024-08-07 | $24.97M 10-Q · filed 2024-08-07 | $35.82M derived: sum of 3 quarters · filed 2025-03-03 | $40.63M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $11.92M 10-Q · filed 2024-05-06 | $22.78M derived: sum of 2 quarters · filed 2025-03-03 | $27.59M derived: sum of 3 quarters · filed 2025-03-03 | $30.99M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $10.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $15.66M derived: sum of 2 quarters · filed 2025-03-03 | $19.07M derived: sum of 3 quarters · filed 2025-03-03 | $22.60M 10-K · filed 2025-03-03 |
| 2022-09-30 | $4.81M 10-Q · filed 2023-11-09 | $8.21M derived: sum of 2 quarters · filed 2023-11-09 | $11.74M 10-Q · filed 2023-11-09 | $14.51M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $3.40M 10-Q · filed 2023-08-09 | $6.93M 10-Q · filed 2023-08-09 | $9.70M derived: sum of 3 quarters · filed 2024-02-27 | $12.51M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $3.53M 10-Q · filed 2023-05-09 | $6.30M derived: sum of 2 quarters · filed 2024-02-27 | $9.11M derived: sum of 3 quarters · filed 2024-02-27 | $11.39M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $5.58M derived: sum of 2 quarters · filed 2024-02-27 | $7.86M derived: sum of 3 quarters · filed 2024-02-27 | $10.44M 10-K · filed 2024-02-27 |
| 2021-09-30 | $2.81M 10-Q · filed 2022-11-08 | $5.09M derived: sum of 2 quarters · filed 2022-11-08 | $7.67M 10-Q · filed 2022-11-08 | $9.18M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $2.28M 10-Q · filed 2022-08-08 | $4.86M 10-Q · filed 2022-08-08 | $6.37M derived: sum of 3 quarters · filed 2022-08-08 | $7.54M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $2.58M 10-Q · filed 2022-05-09 | $4.09M derived: sum of 2 quarters · filed 2022-05-09 | $5.26M derived: sum of 3 quarters · filed 2022-05-09 | $6.05M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.68M derived: sum of 2 quarters · filed 2022-03-01 | $3.47M derived: sum of 3 quarters · filed 2022-03-01 | $3.90M 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.17M 10-Q · filed 2021-11-09 | $1.96M derived: sum of 2 quarters · filed 2021-11-09 | $2.38M 10-Q · filed 2021-11-09 | $2.91M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $786.00K 10-Q · filed 2021-08-09 | $1.21M 10-Q · filed 2021-08-09 | $1.74M derived: sum of 3 quarters · filed 2022-03-01 | $2.22M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $425.00K 10-Q · filed 2021-05-10 | $956.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.44M derived: sum of 3 quarters · filed 2022-03-01 | $1.94M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $531.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.01M derived: sum of 2 quarters · filed 2022-03-01 | $1.52M derived: sum of 3 quarters · filed 2022-03-01 | $1.83M 10-K · filed 2022-03-01 |
| 2019-09-30 | $480.00K 10-Q · filed 2020-11-10 | $986.00K derived: sum of 2 quarters · filed 2020-11-10 | $1.30M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $506.00K 10-Q · filed 2020-08-11 | $818.00K 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |